BioPharmSignal logoBioPharmSignal

Biotech News

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

Cellectar Biosciences (CLRB)Cellectar BiosciencesCompany update

CLRB (CLRB) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is clrb.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

CLRBCellectar Biosciences2026-07-15 11:30 EST

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

CLRBCellectar Biosciences2026-08-13 11:15 EST

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

BMEABiomea Fusion2026-06-05 23:32 EST

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

IDYAIDEAYA Biosciences2026-07-17 13:00 EST

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

IDYAIDEAYA Biosciences2026-06-15 10:00 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

COGTCogent Biosciences2026-06-12 12:00 EST

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

SNDXSyndax Pharmaceuticals2026-06-11 11:00 EST

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

REPLReplimune Group2026-07-30 22:15 EST

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

View all latest news

Cellectar Biosciences

Phospholipid Drug Conjugate Platform Cellectar Biosciences develops cancer therapies using its Phospholipid Drug Conjugate platform, which is designed to deliver radioisotopes selectively to malignant cells while limiting off-target exposure. Iopofosine I 131 Iopofosine I 131 is the company’s lead radioconjugate and has produced clinical...

Recent company news

CLRBCellectar Biosciences2026-08-13 11:15 EST

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CLRBCellectar Biosciences2026-07-30 12:05 EST

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

CLRBCellectar Biosciences2026-07-15 11:30 EST

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

CLRBCellectar Biosciences2026-06-01 12:05 EST

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

CLRBCellectar Biosciences2026-05-14 11:15 EST

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Stock data

Close
2.56 USD
Market cap
21.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States